Ocular Therapeutix Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 51.96, 121.47, 320.02, 667.62, 989.49 ], "ebit_estimate": [ -366.24, -343.31, -274.28, -9.48, 239.97 ], "ebitda_estimate": [ -379, -301, -164, 42.5, 472.6 ], "net_income_estimate": [ -356.83, -330.2, -217.07, -7.11, 230.85 ], "per_share_eps_estimate": [ -1.57, -1.41, -1.21, -0.24, 0.87 ], "eps_nri_estimate": [ -1.6, -1.44, -1.17, -0.19, 0.91 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ -363, -336.87, -267.18, -1.58, 249.08 ], "operating_cash_flow_per_share_estimate": [ 0.28, 0.33, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -77, null, null, null, null ], "gross_margin_estimate": [ 88.5, 87.8, 87.1, 87.83, 89.65 ], "operating_cash_flow_estimate": [ 62.75, 73.95, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 11.8 ], "long_term_growth_rate_mean": 6.53, "long_term_revenue_growth_rate_mean": "87.83", "future_per_share_eps_estimate_growth": 5.74, "future_eps_nri_estimate_growth": 6.53, "future_revenue_estimate_growth": 87.83, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 13.2, 14.02, 13.86, 13.27, 18.19, 35.5, 48.88, 100.62 ], "ebit_estimate": [ -88.92, -91.16, -96.75, -85.13, -79.83, -69.8, -60.07, -38.34 ], "ebitda_estimate": [ -94, -95, -97, -99, -93, -69, -41, -38 ], "net_income_estimate": [ -87.47, -89.39, -93.27, -78.99, -73.63, -63.53, -57.07, -38.34 ], "per_share_eps_estimate": [ -0.39, -0.39, -0.4, -0.39, -0.38, -0.33, -0.3, -0.16 ], "eps_nri_estimate": [ -0.4, -0.4, -0.41, -0.41, -0.39, -0.34, -0.31, -0.16 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ -87.97, -89.72, -93, -83.69, -78.5, -68.47, -58.74, -38.34 ], "operating_cash_flow_per_share_estimate": [ 0.33, 0.39, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ 89, 89, 87.5, 88.5, 88.5, 88.5, 87, 90 ], "operating_cash_flow_estimate": [ 73.95, 87.4, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 6.53, "long_term_revenue_growth_rate_mean": "87.83", "future_per_share_eps_estimate_growth": 5.74, "future_eps_nri_estimate_growth": 6.53, "future_revenue_estimate_growth": 87.83, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }